Wedbush Securities Reiterates Neutral Rating, Raises Price Target On Boston Scientific On 4Q Recap

In a report published Thursday, Wedbush Securities analyst Tao Levy reiterated a Neutral rating on Boston Scientific Corporation BSX, and raised the price target from $16.00 to $17.00. In the report, Wedbush Securities noted, "BSX reported a generally in-line quarter, led by strength from its Interventional Cardiology, CRM, and Urology/Women's Health businesses. Overall, we are encouraged that the company's new product launches are gaining traction, and we have a favorable opinion of its pipeline. However, we believe BSX's share price fairly reflects its risk/reward outlook." Boston Scientific closed on Wednesday at $14.96.